Weekly Tech+Bio Highlights #79: A Pharma Factory in an Egg
Lilly's $2.75B generative chemistry deal and why AI research might be locked into 'hypernormal' science
This week pharma keeps signing billion-dollar AI drug discovery deals, but the upfront commitments are a fraction of the headline numbers, with the rest contingent on the technology actually delivering. Meanwhile, the most surprising entry comes from a direction nobody was watching, and it involves poultry.